ABUS Arbutus Biopharma Corp

8-K Current Report

Filed: March 3, 2026

Health Care

Pharmaceutical Preparations

Arbutus Biopharma Corp (ABUS) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Moderna to pay $950M noncontingent lump sum to Arbutus/Genevant on or before July 8, 2026, resolving all LNP patent litigation
• Additional $1.3B contingent payment triggered if Federal Circuit affirms rejection of Moderna's §1498 defense; prorated if only partial win; repayable with interest if victory later overturned

+3 more insights

Item 8.01 · Other Events

• Arbutus and partner Genevant entered a Settlement Agreement, announced March 3, 2026 — nature, terms, and financial impact disclosed only via Exhibit 99.1
• Settlement agreements typically resolve patent/licensing disputes; material to ABUS given its LNP (lipid nanoparticle) IP monetization strategy

+1 more insights

Get deeper insights on Arbutus Biopharma Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.